Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma

In the opening segment, the moderator introduces a panel of experts who set the stage for discussing current challenges in multiple myeloma. The experts emphasize that despite significant progress with immunotherapies and cellular treatments, the disease remains complex, and these advances have added new layers to clinical decision-making. Panelists highlight persistent unmet needs, particularly for patients in the third-line setting who are triple-class exposed and may be ineligible for CAR T-cell therapy. They note that bispecific antibodies hold promise in bridging this gap. The conversation then turns to recent therapeutic breakthroughs, with experts underscoring the transformative impact of bispecific antibodies and CAR T-cell therapies, which have achieved response rates exceeding 60% in heavily pretreated patients. For the first time, emerging data suggest the possibility of plateauing survival curves in myeloma, a sign of meaningful, durable benefit.